Sponsored by Prasfarma In the highly regulated world of pharmaceuticals, analytical development plays a pivotal role in Investigational Medicinal Product Dossier (IMPD) projects. These projects are critical for obtaining clinical trial authorization and ensuring the safety, efficacy, and quality of
Prasfarma has committed €32 million to expanding its facilities in Manlleu, reinforcing its focus on technological innovation and sustainability. The investment aims to enhance the production of oncology drugs while meeting the highest industry standards, including Annex I of Good Manufacturing
The Annex 1 of the European Union’s Good Manufacturing Practice (EU GMP) guidelines is a critical document that outlines the requirements for the manufacture of sterile medicinal products. The revised EU GMP Annex 1 requirements came into force in August
Prasfarma Contract Manufacturing & Development (CDMO) Profile Prasfarma is a pharmaceutical company specializing in the manufacturing of cytostatic and highly potent products (HPAPI). With over 80 years of experience, we are a leader in the industry, offering a wide range
Stay ahead of trends and best practices
Exclusive downloads and podcasts
Get invites to special events and meetups 
Help us find the most innovative and trusted suppliers in Pharma and Biotech.
